Immunocore/$IMCR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Immunocore

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Ticker

$IMCR
Sector
Primary listing

Employees

493

Immunocore Metrics

BasicAdvanced
$1.6B
-
-$0.41
0.77
-

What the Analysts think about Immunocore

Analyst ratings (Buy, Hold, Sell) for Immunocore stock.

Bulls say / Bears say

In 2024, KIMMTRAK net sales increased 30% year-on-year to $310.0 million, driven by Q4 sales of $84.1 million and marking 11 successive quarters of growth (Immunocore.com).
In Q1 2025, Immunocore generated $93.9 million in net product revenue, a 33% year-on-year increase, reflecting strong KIMMTRAK uptake in both the U.S. and Europe (Nasdaq).
In Q2 2025, KIMMTRAK net product sales rose 30% year-on-year to $98.0 million, with 15% growth in the U.S. and 71% growth in Europe and international regions, underscoring robust global expansion (GlobeNewswire).
Research and development expenses surged to $222.2 million in 2024, up 36% year-on-year, reflecting aggressive pipeline investment that heightens cash burn risk (Immunocore.com).
R&D spend climbed further to $69.0 million in Q2 2025 from $51.1 million a year earlier, intensifying pressure on profitability outside of KIMMTRAK sales (GlobeNewswire).
Selling, general and administrative costs rose to $155.8 million in 2024, up from $144.5 million in 2023, indicating elevated overhead that could erode margins if sales growth slows (Immunocore.com).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

Immunocore Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Immunocore Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMCR

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs